Adjuvant interferon therapy for malignant melanoma: The debate

Chinese Journal of Cancer

Volumn 29, Issue 11, 2010, Pages 907-913

  Zhou, Qiang ^a   Zhang, Xiao Shi ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Adjuvant therapy; Clinical trial; Interferon; Melanoma

Indexed keywords

ALPHA2B INTERFERON; AUTOANTIBODY; INTERFERON; INTERLEUKIN 2; ISOTRETINOIN; PEGINTERFERON;

AUTOIMMUNITY; CANCER ADJUVANT THERAPY; CANCER RELAPSE; CANCER SURVIVAL; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; FEASIBILITY STUDY; HIGH RISK PATIENT; HUMAN; LOW DRUG DOSE; LYMPH NODE METASTASIS; MAINTENANCE THERAPY; MELANOMA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PERSONALIZED MEDICINE; PROCESS OPTIMIZATION; PROGNOSIS; REVIEW; SKIN DEFECT; SKIN ULCER; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT;

EID: 79955788962     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.010.10169     Document Type: Review

References (36)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002 [J]. CA Cancer J Clin, 2005, 55(2): 74-108.
2. Cui CL, Chi ZH, Yuan XQ, et al. Endostar combined with chemotherapy as first line therapy for the treatment of stage IV melanoma, a phase II clinical study [J]. Chin J Clin Oncol, 2009, 14(1): 74-79. [in Chinese]
3. Eigentler TK, Caroli UM, Radny P, et al. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials [J]. Lancet Oncol, 2003, 4(12): 748-759.
4. White RR, Stanley WE, Johnson JL, et al. Long-term survival in 2, 505 patients with melanoma with regional lymph node metastasis [J]. Ann Surg, 2002, 235(6): 879-887.
5. Eggermont AM, Gore M. Randomized adjuvant therapy trials in melanoma: surgical and systemic [J]. Semin Oncol, 2007, 34(6): 509-515.
6. Hauschild A. Adjuvant interferon alfa for melanoma: new evidencebased treatment recommendations? [J]. Curr Oncol, 2009, 16(3): 3-6.
7. NCCN Clinical Practice Guidelines in OncologyTM: Melanoma, v. 2.2010 [OL]. http://www.nccn.org/professionals/physician_gls/PDF/melanoma.pdf
8. Dummer R, Hauschild A, Pentheroudakis G. Cutaneous malignant melanoma: ESMO clinical recommendations for diagnosis, treatment and follow-up [J]. Ann Oncol, 2009, 20(Suppl 4): 129-131.
9. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684 [J]. J Clin Oncol, 1996, 14(1): 7-17.
10. Kirkwood JM, Ibrahim JG, Sondak VK, et al. High-and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190 [J]. J Clin Oncol, 2000, 18(12): 2444-2458.
11. Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/ S9512/C509801 [J]. J Clin Oncol, 2001, 19(9): 2370-2380.
12. Kirkwood JM, Bender C, Agarwala S, et al. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy [J]. J Clin Oncol, 2002, 20(17): 3703-3718.
13. Grob JJ, Dreno B, de la Salmonière P, et al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma [J]. Lancet, 1998, 351(9120): 1905-1910.
14. Pehamberger H, Soyer HP, Steiner A, et al. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group [J]. J Clin Oncol, 1998, 16(4): 1425-1429.
15. Hancock BW, Wheatley K, Harris S, et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study-United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon alfa-2a in high-risk resected malignant melanoma [J]. J Clin Oncol, 2004, 22(1): 53-61.
16. Cameron DA, Cornbleet MC, Mackie RM, et al. Adjuvant interferon alpha 2b in high risk melanoma-the Scottish study [J]. Br J Cancer, 2001, 84(9): 1146-1149.
17. Cascinelli N, Belli F, MacKie RM, et al. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial [J]. Lancet, 2001, 358(9285): 866-869.
18. Garbe C, Radny P, Linse R, et al. Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis [J]. Ann Oncol, 2008, 19(6): 1195-1201.
19. Hauschild A, Weichenthal M, Rass K, et al. Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >=1.5 mm tumor thickness: results of a randomized phase III DeCOG trial [J]. J Clin Oncol, 2010, 28(5): 841-846.
20. Eggermont AM, Suciu S, MacKie R, et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial [J]. Lancet, 2005, 366(9492): 1189-1196.
21. Pectasides D, Dafni U, Bafaloukos D, et al. Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma [J]. J Clin Oncol, 2009, 27(6): 939-944.
22. Eggermont AM, Suciu S, Santinami M, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial [J]. Lancet, 2008, 372(9633): 117-126.
23. Kirkwood JM, Manola J, Ibrahim J, et al. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma [J]. Clin Cancer Res, 2004, 10(5): 1670-1677.
24. Wheatley K, Ives N, Hancock BW, et al. Does adjuvant interferon-α for high risk melanoma provide a worthwhile benefit? A metaanalysis of the randomised trials [J]. Cancer Treat Rev, 2003, 29(4): 241-252.
25. Wheatley K, Ives N, Eggermont A, et al. Interferon-α as adjuvant therapy for melanoma: An individual patient data meta-analysis of randomised trials [abstract]. Proc Am Soc Clin Oncol, 2007, 25: 478S.
26. Mocellin S, Pasquali S, Rossi CR, et al. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis [J]. J Natl Cancer Inst, 2010, 102(7): 493-501.
27. Ascierto PA, Kirkwood JM. Adjuvant therapy of melanoma with interferon: lessons of the past decade [J]. J Transl Med, 2008, 6: 62.
28. Eggermont AM, Testori A, Marsden J, et al. Utility of adjuvant systemic therapy in melanoma [J]. Ann Oncol, 2009, 20(Suppl 6): 30-34.
29. Eggermont AM, Suciu S, Testori A, et al. Ulceration of primary melanoma and responsiveness to adjuvant interferon therapy: Analysis of the adjuvant trials EORTC18952 and EORTC18991 in 2, 644 patients [J]. J Clin Oncol, 2009, 27: 15s, (suppl; abstr 9007).
30. Eggermont AM, Suciu S, Santinami M, et al. EORTC 18991: Longterm adjuvant pegylated interferon-alpha2b (PEG-IFN) compared to observation in resected stage III melanoma, final results of a randomized phase III trial [J]. J Clin Oncol, 2007, 25(18S): 8504.
31. Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon [J]. N Engl J Med, 2006, 354(7): 709-718.
32. Dafni U, Pectasides D, Tsoutsos D, et al. Prognostic significance of autoimmunity during adjuvant treatment of melanoma with interferon: Updated follow-up [J]. J Clin Oncol, 2008, 26(suppl): 9024.
33. Stuckert JJ, Tarhini AA, Lee S, et al. Interferon alfa-induced autoimmunity and serum S100 levels as predictive and prognostic biomarkers in high-risk melanoma in the ECOG-intergroup phase II trial E2696 [J]. Proc Am Soc Clin Oncol, 2007, 25: 473S.
34. Satzger I, Meier A, Schenck F, et al. Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low-dose interferon alpha [J]. Int J Cancer, 2007, 121(11): 2562-2566.
35. Bouwhuis MG, Suciu S, Collette S, et al. Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon [J]. J Natl Cancer Inst, 2009, 101(12): 869-877.
36. Bouwhuis MG, Suciu S, Testori A, et al. Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies--EORTC 18991 [J]. J Clin Oncol, 2010, 28(14): 2460-2466.